Enovis (NYSE:ENOV) Stock Gets Price Target Boost from Wells Fargo & Company

Enovis (NYSE:ENOV) had its price objective raised by analysts at Wells Fargo & Company from $33.00 to $37.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 36.25% from the stock’s current price.

ENOV has been the topic of a number of other reports. BMO Capital Markets set a $27.00 target price on shares of Enovis in a report on Tuesday, September 1st. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Canaccord Genuity Group lowered their price objective on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, August 17th. Finally, Citigroup restated a “market outperform” rating on shares of Enovis in a research note on Wednesday, September 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Enovis Trading Down 5.1%

NYSE:ENOV opened at $27.16 on Friday. The stock’s 50 day moving average price is $19.86 and its 200 day moving average price is $23.07. The company has a market capitalization of $1.57 billion, a PE ratio of -1.40 and a beta of 1.31. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis has a 52-week low of $16.70 and a 52-week high of $32.41.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.77 by $0.11. The company had revenue of $558.73 million for the quarter, compared to analyst estimates of $557.12 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The firm’s revenue was up 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 earnings per share. On average, research analysts anticipate that Enovis will post 3.15 EPS for the current year.

Insider Activity at Enovis

In related news, CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction on Friday, September 4th. The shares were bought at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the purchase, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Oliver Engert bought 5,140 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was bought at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the acquisition, the insider owned 61,238 shares of the company’s stock, valued at approximately $1,191,691.48. This trade represents a 9.16% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 23,293 shares of company stock worth $449,599 over the last quarter. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Several institutional investors have recently bought and sold shares of the company. IFP Advisors Inc raised its position in Enovis by 5,590.5% during the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after buying an additional 1,174 shares during the last quarter. Allworth Financial LP acquired a new stake in shares of Enovis in the 2nd quarter worth $36,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Enovis in the second quarter valued at about $39,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Enovis in the second quarter valued at about $48,000. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Enovis in the third quarter valued at about $55,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis raised its 2026 adjusted EPS guidance to $3.58–$3.79 and authorized a $200 million share-repurchase program, improving its earnings outlook and offering a potential source of share demand. Enovis raises guidance and authorizes buyback
• Positive Sentiment: Third-quarter adjusted EPS was $0.88, above consensus estimates of about $0.76–$0.77 and up from $0.75 a year earlier. Reports highlighted a swing to quarterly profit as a key reason the shares advanced. Enovis climbs on third-quarter profit and sales
• Positive Sentiment: Analyst sentiment also improved: Needham raised its price target to $38 and BTIG lifted its target to $42, both maintaining Buy ratings.
• Neutral Sentiment: Revenue was $558.7 million, slightly above estimates of $557.1 million and 1.8% higher year over year—solid but modest growth. Enovis third-quarter earnings and revenue beat estimates

Enovis Company Profile

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.